We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesUnicycive Therapeutics Inc

Unicycive Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.605 USD -0.17 ( 4.63%)
Last update at 2026-11-12T15:36:00Z
VOLUME
227013
Market Cap
64.35M

Momentum Score

…

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.56
Low
3.70
High
52 Week Price Range
0.20
Low
1.82
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.78
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.21
ROE
-121.76%
Net Debt
-8.89M
ROCE
544.81%
Diluted EPS TTM
-0.46

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -18.06M -10.02M -2.26M -2.17M -
Net income -18.06M -10.63M -2.51M -2.30M -
Selling general administrative 6.57M 2.90M 1.00M 1.17M -
Gross profit 0.95M - - - -
Reconciled depreciation 0.16M 0.01M - - -
Ebit -18.21M -8.99M -2.02M -1.96M -0.95M
Ebitda -18.05M -8.98M -2.02M -1.96M -
Depreciation and amortization 0.16M 0.01M - -0.06M -
Operating income -18.05M -8.98M -2.02M -1.96M -
Other operating expenses 19.00M 8.98M 2.02M 1.96M -
Interest expense 0.01M 0.63M 0.24M 0.14M 0.00M
Net interest income -0.01M -0.63M -0.24M -0.14M -
Income tax expense 0.01M 0.61M 0.24M 0.14M -
Total revenue 0.95M 0.00M 0.00M 0.00M -
Total operating expenses 19.00M 8.98M 2.02M 1.96M -
Total other income expense net -0.01M -1.04M -0.24M -0.20M -
Net income from continuing ops -18.06M -10.02M -2.26M -2.17M -
Net income applicable to common shares - -10.02M -2.26M -2.17M -1.12M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 14.19M 2.82M 18.74M 0.20M 0.02M
Other current assets 3.70M 2.19M 1.83M 0.00M 0.00M
Total liab 18.00M 3.28M 2.26M 2.88M 0.90M
Total stockholder equity -3.81M -0.47M 16.48M -2.67M -0.88M
Other current liab 16.37M 2.24M 1.21M 0.18M 0.12M
Common stock 0.04M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.04M 0.01M 0.01M 0.01M 0.01M
Retained earnings -64.54M -34.00M -15.94M -5.92M -3.66M
Cash 9.70M 0.46M 16.58M 0.00M 0.01M
Total current liabilities 17.53M 3.28M 2.10M 2.88M 0.90M
Current deferred revenue 0.00M - - - -
Net debt -8.89M -0.30M -16.27M 2.51M 0.45M
Short term debt 0.34M 0.15M 0.15M 2.51M 0.46M
Short long term debt 0.02M 0.05M 0.03M 2.51M 0.46M
Short long term debt total 0.81M 0.15M 0.31M 2.51M 0.46M
Other stockholder equity 60.70M 33.52M 32.41M 3.24M 2.77M
Property plant equipment - - 0.33M - -
Total current assets 13.40M 2.64M 18.41M 0.20M 0.02M
Net tangible assets - - 16.48M -2.67M -0.88M
Accounts payable 0.82M 0.89M 0.74M 0.18M 0.32M
Common stock total equity - - - 0.01M 0.01M
Non current assets total 0.79M 0.17M 0.33M 0.00M 0.00M
Capital lease obligations 0.79M 0.15M 0.31M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.00M -0.03M - - -
Change to liabilities - 1.24M -0.07M 0.31M 0.03M
Total cashflows from investing activities - -0.03M -0.03M -0.03M -0.03M
Net borrowings - -0.01M 1.42M 1.42M 0.55M
Total cash from financing activities -0.47M 22.38M 1.44M 1.17M 0.80M
Change to operating activities - -1.35M -0.10M -0.00M -0.03M
Net income -18.06M -10.02M -2.26M -2.17M -1.12M
Change in cash -16.12M 16.58M -0.01M -0.01M 0.03M
Begin period cash flow 16.58M 0.00M 0.01M 0.03M -
End period cash flow 0.46M 16.58M 0.00M 0.01M 0.03M
Total cash from operating activities -15.65M -5.77M -1.46M -1.18M -0.78M
Issuance of capital stock 0.01M 22.27M 0.14M 1.17M -
Depreciation 0.16M 0.01M 0.01M 0.01M 0.01M
Other cashflows from financing activities -0.48M 1.47M 1.46M 0.01M -0.12M
Change to netincome - 3.85M 0.79M 0.59M 0.23M
Capital expenditures 0.00M 0.03M 0.03M 0.03M 0.03M
Change in working capital 1.18M -0.10M -0.17M 0.30M -
Stock based compensation 1.05M 0.97M 0.23M 0.02M -
Other non cash items 0.02M 3.25M 0.74M 0.66M -
Free cash flow -15.65M -5.80M -1.46M -1.18M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
UNCY
Unicycive Therapeutics Inc		 -0.17
4.63%		 3.60 - - 62.82 2.31 16.63 -1.03
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Unicycive Therapeutics Inc

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

4300 El Camino Real, Los Altos, CA, United States, 94022

650 351 4495

https://unicycive.com

14

Name Title Year Born
Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, CEO & Pres 1973
Mr. John W. Townsend CPA Chief Financial Officer 1962
Dr. Pramod Gupta Ph.D. Exec. VP of Pharmaceutical & Bus. Operations 1960
Mr. Douglas Jermasek M.B.A. Exec. VP of Corp. Strategy NA
Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, CEO & President 1973
Dr. Pramod Gupta Ph.D. Executive Vice President of Pharmaceutical & Business Operations 1960
Mr. Douglas Jermasek M.B.A. Executive Vice President of Corporate Strategy 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…